Summarized by Masters of Longevity from Nature - Main.
Report on research probing why 10–15% of patients show little or no weight loss from GLP-1–based obesity drugs and emerging hypotheses.
Key Takeaways
- “There is tremendous heterogeneity” in the response to these medications, says Daniel Drucker , an endocrinologist at the University of Toronto in Canada, whose work aided in the development of GLP-1 drugs.
- Those tantalizing possibilities have made people’s individualized responses to GLP-1s a key line of enquiry for obesity scientists.
